These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9919340)

  • 41. Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.
    Bardhi E; Marchetti C; Scopelliti A; Musacchio L; Tomao F; Schiavi M; Carraro C; Palaia I; Monti M; Muzii L; Benedetti Panici P
    Expert Opin Investig Drugs; 2019 Aug; 28(8):667-673. PubMed ID: 31353973
    [No Abstract]   [Full Text] [Related]  

  • 42. [Studies on additional Iscador therapy in the management of women with surgically and radiotherapeutically treated genital carcinoma].
    Leroi R
    Gynaecologia; 1969; 167(3):158-70. PubMed ID: 4305038
    [No Abstract]   [Full Text] [Related]  

  • 43. Concerns with "maintenance chemotherapy" for patients with recurrent platinum-sensitive ovarian cancer.
    Markman M
    Gynecol Oncol; 1999 Jun; 73(3):469-70; author reply 470-2. PubMed ID: 10366485
    [No Abstract]   [Full Text] [Related]  

  • 44. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
    Markman M
    Gynecol Oncol; 2001 Apr; 81(1):1-2. PubMed ID: 11277641
    [No Abstract]   [Full Text] [Related]  

  • 45. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
    Lee HP; Seo SS; Ryu SY; Kim JH; Bang YJ; Park SY; Nam JH; Kang SB; Lee KH; Song YS
    Gynecol Oncol; 2008 Jun; 109(3):359-63. PubMed ID: 18405948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemotherapy for advanced or recurrent cervical cancer.
    Kamura T; Ushijima K
    Taiwan J Obstet Gynecol; 2013 Jun; 52(2):161-4. PubMed ID: 23915846
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
    Lamond JP; Mehta MP; Boothman DA
    J Neurooncol; 1996 Oct; 30(1):1-6. PubMed ID: 8864997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Radiotherapy concomitant with cisplatin chemotherapy in the treatment of cancer of the cervix uteri].
    Bild E; Buiuc A; Albulescu E
    Rev Med Chir Soc Med Nat Iasi; 1995; 99(1-2):99-102. PubMed ID: 9524663
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.
    Mistry P; Stewart AJ; Dangerfield W; Baker M; Liddle C; Bootle D; Kofler B; Laurie D; Denny WA; Baguley B; Charlton PA
    Anticancer Drugs; 2002 Jan; 13(1):15-28. PubMed ID: 11914637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemotherapy for recurrent and metastatic cervical cancer.
    Tao X; Hu W; Ramirez PT; Kavanagh JJ
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Camptothecins: Unfolding Their Anticancer Potential. Proceedings of a conference. March 17-20, 2000, Arlington, Virginia, USA.
    Ann N Y Acad Sci; 2000; 922():xi-xii, 1-363. PubMed ID: 11193929
    [No Abstract]   [Full Text] [Related]  

  • 52. 5-aza-2'-deoxycytidine in advanced or recurrent cancer of the uterine cervix.
    Vermorken JB; Tumolo S; Roozendaal KJ; Guastalla JP; Splinter TA; Renard J
    Eur J Cancer; 1991; 27(2):216-7. PubMed ID: 1709026
    [No Abstract]   [Full Text] [Related]  

  • 53. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
    Hoffman MA; Blessing JA; Morgan M
    Gynecol Oncol; 2000 Dec; 79(3):463-5. PubMed ID: 11104620
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical experience with topotecan in relapsed ovarian cancer.
    Herzog TJ
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S3-7. PubMed ID: 13129489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Topoisomerase enzymes as drug targets.
    Guichard SM; Danks MK
    Curr Opin Oncol; 1999 Nov; 11(6):482-9. PubMed ID: 10550012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors.
    Wakelee HA; Sikic BI
    Clin Lung Cancer; 2005 Sep; 7 Suppl 1():S6-12. PubMed ID: 16159420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rubitecan.
    Clark JW
    Expert Opin Investig Drugs; 2006 Jan; 15(1):71-9. PubMed ID: 16370935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA topoisomerase I inhibitors.
    Takimoto CH; Kieffer LV; Arbuck SG
    Cancer Chemother Biol Response Modif; 1997; 17():80-113. PubMed ID: 9551210
    [No Abstract]   [Full Text] [Related]  

  • 59. Secondary therapy for epithelial ovarian cancer--1994.
    Sutton GP
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):32-6. PubMed ID: 8091239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
    Lin H; Changchien CC
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.